DeepMed Research

Avexitide

Generic Name: Avexitide

Drug Type: Small Molecule

Chemical Formula: C_₁₄₉H_₂₃₄N_₄₀O_₄₇S

CAS Number: 133514-43-9

Unique Ingredient Identifier: 5313W10MYT

Background: Avexitide is under investigation in clinical trial NCT02996812 (Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia).

Clinical Trials

The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

Phase 2

Not yet recruiting

Conditions: Genetic Predisposition
Type2diabetes

Interventions: Biological: Exendin 9-39
Other: Saline

First Posted Date: 2025-05-15

Last Posted Date: 2025-05-15

Lead Sponsor: Mayo Clinic

Target Recruit Count: 80

Registration Number: NCT06972407

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Avexitide for Treatment of Post-Bariatric Hypoglycemia

Phase 3

Recruiting

Conditions: Post Bariatric Hypoglycemia

Interventions: Other: Placebo
Drug: Avexitide

First Posted Date: 2024-12-24

Last Posted Date: 2025-05-07

Lead Sponsor: Amylyx Pharmaceuticals Inc.

Target Recruit Count: 75

Registration Number: NCT06747468

Locations: 🇺🇸
Stanford Health Care - Endocrinology Clinic, Stanford, California, United States
🇺🇸
University of Colorado Health Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸
East Coast Institute for Research, Jacksonville, Florida, United States

and more 18 locations

Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia

Phase 2

Completed

Conditions: Acquired Hyperinsulinemic Hypoglycemia

Interventions: Drug: Avexitide

First Posted Date: 2020-12-03

Last Posted Date: 2023-06-09

Lead Sponsor: Dr. Tracey McLaughlin, MD

Target Recruit Count: 25

Registration Number: NCT04652479

Locations: 🇺🇸
Clinical and Translational Research Unit, Palo Alto, California, United States

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Phase 2

Completed

Conditions: Postbariatric Hypoglycemia

Interventions: Drug: exendin 9-39
Other: Placebo

First Posted Date: 2017-12-14

Last Posted Date: 2022-07-18

Lead Sponsor: Eiger BioPharmaceuticals

Target Recruit Count: 18

Registration Number: NCT03373435

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 2 locations

The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D

Not Applicable

Completed

Conditions: Glucose Metabolism Disorders

Interventions: Drug: Placebo Oral Tablet
Drug: Saline
Drug: Metformin
Drug: Exendin (9-39)

First Posted Date: 2017-08-11

Last Posted Date: 2018-07-09

Lead Sponsor: University Hospital, Gentofte, Copenhagen

Target Recruit Count: 15

Registration Number: NCT03246451

Locations: 🇩🇰
Center for Diabetes Research, Gentofte, Copenhagen, Denmark

Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines

Not Applicable

Completed

Conditions: Glucose Metabolism Disorders

Interventions: Drug: Placebo Oral Tablet
Drug: Acarbose
Drug: Placebo Saline
Drug: Exendin (9-39)

First Posted Date: 2017-08-07

Last Posted Date: 2020-03-26

Lead Sponsor: University Hospital, Gentofte, Copenhagen

Target Recruit Count: 15

Registration Number: NCT03241303

Locations: 🇩🇰
Center for Diabetesresearch, Hellerup, Denmark

Cardiovascular Effects of GLP-1 Receptor Activation

Phase 4

Completed

Conditions: Obesity
PreDiabetes

Interventions: Other: hypocaloric diet
Drug: Liraglutide
Drug: Sitagliptin
Drug: Placebos
Drug: Exendin (9-39)

First Posted Date: 2017-04-05

Last Posted Date: 2022-10-18

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 329

Registration Number: NCT03101930

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia

Phase 1

Completed

Conditions: Hyperinsulinemia Hypoglycemia

Interventions: Drug: Exendin (9-39)

First Posted Date: 2016-12-19

Last Posted Date: 2024-12-04

Lead Sponsor: Tracey McLaughlin

Target Recruit Count: 9

Registration Number: NCT02996812

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Regulation of Insulin Secretion by the GLP-1 Receptor

Phase 4

Terminated

Conditions: Insulin Secretion

Interventions: Drug: Dexamethasone
Drug: Exendin (9-39)
Other: Hyperglycemic Clamp

First Posted Date: 2016-07-26

Last Posted Date: 2024-12-12

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 6

Registration Number: NCT02844907

Locations: 🇺🇸
Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States

Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia

Phase 2

Completed

Conditions: Post Bariatric Hypoglycemia

Interventions: Drug: Lyo avexitide
Drug: Liq avexitide

First Posted Date: 2016-05-13

Last Posted Date: 2020-11-13

Lead Sponsor: Tracey McLaughlin

Target Recruit Count: 19

Registration Number: NCT02771574

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy